Atara Biotherapeutics, Inc.
LSE: 0HIY.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Anhco Nguyen
- Employees
- 153
- Headquarters
- South San Francisco, United States
- IPO year
- 2018
- Market cap
- $66.8M
- Website
- https://www.atarabio.com
Loading 0HIY…
Loading profile data…Frequently asked questions about 0HIY
What does Atara Biotherapeutics, Inc. (0HIY.L) do?
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...
Where does 0HIY.L trade?
Atara Biotherapeutics, Inc. (0HIY.L) trades on the London Stock Exchange.
What sector is 0HIY.L in?
Atara Biotherapeutics, Inc. (0HIY.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Atara Biotherapeutics, Inc.?
Anhco Nguyen is the chief executive officer of Atara Biotherapeutics, Inc. (0HIY.L).
Where is Atara Biotherapeutics, Inc. headquartered?
Atara Biotherapeutics, Inc. is headquartered in United States.
Does 0HIY.L pay a dividend?
Atara Biotherapeutics, Inc. (0HIY.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0HIY.L go public?
Atara Biotherapeutics, Inc. (0HIY.L) completed its initial public offering in 2018.